Product Name:(4-Ethoxycarbonylphenyl)boronic acid

IUPAC Name:[4-(ethoxycarbonyl)phenyl]boronic acid

CAS:4334-88-7
Molecular Formula:C9H11BO4
Purity:97%
Catalog Number:CM135619
Molecular Weight:193.99

Packing Unit Available Stock Price($) Quantity
CM135619-100g in stock ǤǤʼn

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:4334-88-7
Molecular Formula:C9H11BO4
Melting Point:-
Smiles Code:C1=C(C(OCC)=O)C=CC(=C1)B(O)O
Density:
Catalog Number:CM135619
Molecular Weight:193.99
Boiling Point:
MDL No:MFCD02179441
Storage:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Momelotinib
GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.